Podcasts about Lung

DAVID WEILL, M.D., is the former Director of the Center for Advanced Lung Disease and Lung and Heart-Lung Transplant Program at Stanford University Medical Center. He is currently the Principal of the Weill Consulting Group which focuses assisting hospitals in improving their transplant programs and developing new programs in the US and throughout the world. David's writing has appeared in the Wall Street Journal, USA Today, Newsweek, and The San Francisco Chronicle. In his new novel, "All That Really Matters," David explores the demands, challenges and complications of a fictional transplant surgeon. We discuss his 25 year career as a lung transplant surgeon and the behind-the-scenes world of medical ethics, corporate greed in medicine and the life and death decisions made in "the selection room," where it is decided who gets a transplant and who doesn't. www.davidweill.com

 From loss and resilience to literary triumph — nurse and author Rhonda McCoy opens up about her life and debut novel Crow. Plus, we peer into the world of cyber and financial security — and why nurses could be the next big targets. The latest Nursing Australia News (04:35) Aussie CDC, Nursing Emergency, Lung screens, and Festival of Nursing 2026 Segment 1: THE CROW (06:55) Segment 2: STOLEN: Understanding Financial Crime (41:30)  Handy Links: KEEPING SAFE ONLINE!  GRAB A COPY of Rhonda McCoy's novel CROW  APNA Workforce Survey - Have YOUR SAY!  APPLY TO BE PART OF FESTIVAL OF NURSING 2026  HOST A NURSING STUDENT AT YOUR WORKPLACE  Click here to get in touch with Nursing Australia (send a text for free from anywhere in the world) #askusanything Higher Ground - Healthcare LeadershipHigher Ground is an essential guide for healthcare leaders, providing practical...Listen on: Apple Podcasts SpotifyHosted & Produced by: Matthew St Ledger & Leith Alexander Produced by: Leith Alexander & Matthew St Ledger

CONTENT WARNUNG SIEHE UNTEN China ist ein fremdes Land für einige unserer Investigatoren und scheinbar fest in der Hand des Kultes. Nach ihrer Ankunft in Shanghai findet unsere Gruppe Verbündete des Neuen Chinas, einer Terrororganisation / Freiheitskämpfer, je nach Blickwinkel. Hong Shi nutzte auf dem Schiff den Apparat, um seine neugefundene Liebe, Kakakatak, zu besuchen. Seine Freunde schleppten ihn wie tot umher, weshalb sie beschlossen, weder den gefährlichen Ho Fang noch Jack Brady aktiv zu suchen. Stattdessen befreiten sie Mr Lung von einem Dämonen, was ihnen seine Dankbarkeit einbrachte und ein Treffen mit Ms Lin. Die Antiquitätenhändlerin hat noch interessante Informationen und Artefakte, beides will sie morgen Abend mit den Investigatoren besprechen. Aber zuvor wenden wir uns Hong Shi zu, gespielt von Manu, der gerade in seinem Hotelzimmer erwacht. In dem Hotel befinden sich, sichtlich schockiert: Fin Edwards, gespielt von Gregor und  Xi Ling Qirui gespielt von Simon und Hong Shi, gespielt von Manu. -- CONTENT WARNUNG: Wir möchten euch darauf hinweisen, dass die in diesem Podcast dargestellten Ereignisse, Charaktere und Szenarien rein fiktiv sind und ausschließlich der Unterhaltung dienen. Unsere Spielrunde ist geprägt von Offenheit und Inklusivität. Wir sind bestrebt, eine einladende und respektvolle Atmosphäre für alle Zuhörerinnen und Zuhörer zu schaffen. Sollten im Verlauf des Spiels Äußerungen oder Darstellungen vorkommen, die heutzutage als problematisch eingestuft werden könnten, so dienen diese ausschließlich der authentischen Darstellung der historischen Epoche und sind nicht Ausdruck unserer persönlichen Ansichten oder Werte. Wir nehmen unsere Verantwortung als Schöpfer von Inhalten ernst und sind uns der Sensibilität solcher Themen bewusst. Daher möchten wir betonen, dass jegliche potenziell problematischen Inhalte kritisch betrachtet und im Kontext der Spielwelt und ihrer Zeit behandelt werden. Unser Ziel ist es, ein spannendes und zugleich respektvolles Spielerlebnis zu bieten. Vielen Dank für euer Verständnis und viel Spaß beim Zuhören! -- Regelsystem: Horror Core 1.0 (auf Patreon verfügbar) Podcast | Rollenspielpodcast (neomancerrpg.wixsite.com) https://www.patreon.com/1W3Rollenspieler Music by: Tabletop Audio - Ambiences and Music for Tabletop Role Playing Games Cover by Gemini

Alice M. Turner, MBChB, PhD - Cross-Talk Between Lung and Liver in Alpha-1 Antitrypsin Deficiency: A Call for Integrated Care

Alice M. Turner, MBChB, PhD - Cross-Talk Between Lung and Liver in Alpha-1 Antitrypsin Deficiency: A Call for Integrated Care

31 Oct 2025 - Lung cancer trial builds momentum, breast cancer study begins

Alice M. Turner, MBChB, PhD - Cross-Talk Between Lung and Liver in Alpha-1 Antitrypsin Deficiency: A Call for Integrated Care

Alice M. Turner, MBChB, PhD - Cross-Talk Between Lung and Liver in Alpha-1 Antitrypsin Deficiency: A Call for Integrated Care

147: I just got back from Europe and I'm so excited to cover today's topic: Lung Harmony. We're in lung season right now, so it's the perfect time to talk about keeping your dog's respiratory system balanced and strong. In this episode, I walk you through my Lung Harmony formula ingredient by ingredient, and explain how herbs like echinacea, elecampane, maize buds, calendula, and gray alder buds work together to support your pup's lungs. Sponsored By: → Pug & Hound Apothecary Check Out Rita: → The Herbal Dog (Book) → Rita's Instagram → Facebook Group → My Courses → My Website and Store Produced By: Drake Peterson

In this World Shared Practice Forum podcast, Dr. Robinder Khemani, co-author of the PALICC-2 guidelines, discusses the real-world application of pediatric ARDS management strategies. Through a case-based conversation, Dr. Khemani shares nuanced insights on intubation timing, ventilator settings, neuromuscular blockade, and rescue therapies, including ECMO. He also introduces the REDvent trial, a novel approach to lung and diaphragm protective ventilation. This content is ideal for clinicians, respiratory therapists, and healthcare educators seeking to deepen their understanding of evidence-informed, physiology-driven care in pediatric acute respiratory distress syndrome. LEARNING OBJECTIVES - Analyze the clinical decision-making process for intubation in pediatric ARDS - Apply PEEP titration techniques to assess lung recruitability in patients with PARDS - Evaluate the role of neuromuscular blockade in maintaining lung protective ventilation - Identify appropriate advanced rescue therapies based on PARDS phenotypes - Explore the principles and outcomes of the REDvent trial in ventilator management AUTHORS Robinder "Roby" Khemani, MD, MsCI Professor of Pediatrics, Vice Chair of Research University of Southern California, Department of Anesthesiology and Critical Care Medicine Children's Hospital Los Angeles Jeffrey Burns, MD, MPH Emeritus Chief Division of Critical Care Medicine Department of Anesthesiology, Critical Care and Pain Medicine Boston Children's Hospital Professor of Anesthesia Harvard Medical School DATE Initial publication date: October 28, 2025. ARTICLE REFERENCED Khemani RG, Bhalla A, Hotz JC, et al. Randomized Trial of Lung and Diaphragm Protective Ventilation in Children. NEJM Evid. 2025;4(6):EVIDoa2400360. doi:10.1056/EVIDoa2400360 TRANSCRIPT https://cdn.bfldr.com/D6LGWP8S/at/47wbxnvxtcpvv54p48gc2v/202510_WSP_Khemani_Transcript.pdf Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open-access thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Khemani RG, Burns JP. Practical Strategies for Management of Patients with Pediatric ARDS. 10/2025. OPENPediatrics. Online Podcast. https://soundcloud.com/openpediatrics/practical-strategies-for-management-of-patients-with-pediatric-ards-by-r-khemani-openpediatrics.

Gastrointestinal complications are common—but often underrecognized—after lung transplantation. From diarrhea and nausea to malabsorption and poor appetite, these challenges can seriously impact recovery and long-term health outcomes.In this episode of the DNS Podcast, host Christina Rollins speaks with Bridget Doyle, MS, RD, LDN, CNSC, a transplant dietitian specializing in lung transplant nutrition. Bridget shares her expertise on identifying, managing, and supporting patients through complex GI issues post-transplant.Listeners will gain insights on:✅ The most frequent GI complications following lung transplant✅ How medications like immunosuppressants and antibiotics affect digestion✅ Practical nutrition strategies for diarrhea, nausea, and poor intake✅ Food safety guidance for immunocompromised patients✅ When to consider enteral or parenteral nutrition support✅ Key labs and nutrients to monitor for optimal recoveryTune in to hear evidence-based strategies for improving GI health and supporting successful long-term outcomes for transplant recipients. Visit us at dnsdpg.org to learn more.

Have you heard of 'butt-breathing'? See omnystudio.com/listener for privacy information.

Early detection saves lives, but today's tools are often invasive, slow, or used too late. In this episode, Breath Diagnostics CEO Ivan Lo explains how a non-invasive breath test can detect volatile organic compounds (VOCs) associated with disease—positioning breath as a first-line screen for early-stage lung cancer and potentially pneumonia and TB. We cover the science (why breath can capture near real-time biological change), sensitivity/specificity signals from 800+ patients, and a go-to-market/regulatory plan that prioritizes post-op pneumonia (shorter trials, no entrenched standard of care) before lung cancer screening. We also discuss platform economics (low-cost disposables, existing LC-MS infrastructure), trial scale and cost, and how breath could support ongoing monitoring after treatment. Investors get a clear view of timelines, risks, and upside; founders get lessons on platform positioning, capital efficiency, and sequencing indications. Highlights include...Why breath (VOCs) can surface disease signals minutes–hours after biological changeFirst-line screening thesis vs. liquid biopsy and CT workflowsEarly data: ~94% sensitivity / 85% specificity across 800+ patients (lung cancer context)Regulatory path: post-op pneumonia first (faster FDA route), lung cancer nextUnit economics: low-cost cartridge + existing LC-MS labs (hub-and-spoke)Clinical design: trial scale, costs, and companion-diagnostic “cocktail” potentialPlatform beyond oncology: pneumonia, TB, inflammation, RUO for pharmaChapters00:00 Intro & why early detection needs a rethink00:47 What Breath Diagnostics does (the “breath bag”)03:34 VOCs 101: why breath can be earlier than blood06:41 First-line screen vs. confirmatory tests08:19 Will this be ubiquitous at annual visits?11:53 Commercialization path & funding realities12:37 Pneumonia first: faster FDA route14:09 Lung cancer timeline & business model15:34 Hospital economics & pneumonia savings18:24 Trial scale/costs; disposable chip economics20:34 Team, funding strategy, and sequencing22:08 Early data and a “false negative” biopsy case24:12 TAM & eligibility (20M Americans qualify)25:06 What success looks like (2–3 years)27:00 Investor closing thoughts

Lung cancer is the leading cause of cancer death in the United States for both men and women. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. This is because the disease shows no symptoms until it has progressed to advanced stages when it is very difficult to treat. The good news is that advances in imaging have made it possible to detect lung cancer early on, when treatment can be highly successful.The Eisenhower Lung Cancer Screening Program evaluates current and former smokers to determine their risk for lung cancer and provides assessment and evaluation for persons at risk for lung cancer.

This new mini-series on Behind the Knife will delve into the technical aspects of the Operative Standards for Cancer Surgery, developed through the American College of Surgeons Cancer Research Program. This first episode highlights the colon cancer operative standard. Hosts: Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a Surgical Oncology fellow at MD Anderson Cancer Center. Guest: George Chang, MD, MS, MHCM, FACS, FASCRS, FSSO is a Professor and the interim Department Chair in the Department of Colon and Rectal Surgery at MD Anderson Cancer Center.   Learning Objectives: The extent of colon mobilization and resection depends on tumor location, with high vascular ligation of the tumor-bearing segment to complete adequate regional lymphadenectomy. The technical steps of right colectomy are reviewed, including high ligation of the ileocolic pedicle at the level of the superior mesenteric vein, and the right branch of the middle colic artery if present. Tips and tricks are discussed to identify vascular structures and avoid central vascular injury. Links to Papers Referenced in this Episode Operative Standards for Cancer Surgery, Volume 1: Breast, Lung, Pancreas, Colon https://www.facs.org/quality-programs/cancer-programs/cancer-surgery-standards-program/operative-standards-for-cancer-surgery/purchase/ Kindle edition: https://www.amazon.com/Operative-Standards-Cancer-Surgery-Section-ebook/dp/B07MWSNFSB Short-term outcomes of complete mesocolic excision versus D2 dissection in patients undergoing laparoscopic colectomy for right colon cancer (RELARC): a randomized, controlled, phase 3, superiority trial Lancet Oncol. 2021 Mar; 22(3):391-401. https://pubmed.ncbi.nlm.nih.gov/33587893/ Impact of Proximal Vascular Ligation on Survival of Patients with Colon Cancer. Ann Surg Oncol. 2018 Jan;25(1):38-45. https://pubmed.ncbi.nlm.nih.gov/27942902/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Lung cancer in nonsmoking individuals is increasing worldwide and currently accounts for 15% to 20% of lung cancer cases globally. Benjamin Solomon, PhD, of the Peter MacCallum Cancer Centre in Melbourne, Australia, discusses the epidemiology and treatment of lung cancer in nonsmoking patients with JAMA Deputy Editor Kristin Walter, MD, MS. Related Content: Lung Cancer in Nonsmoking Individuals ----------------------------------- JAMA Editors' Summary

Viral pneumonia can cause severe lung damage and make recovery long and life-threatening for patients. Current treatments only provide support, not repair, but Northwestern Medicine scientist Benjamin Singer, MD, wants to change that. In this episode, he details a recent discovery from his team that found laboratory-modified T-cells or induced regulatory T-cells (iTregs), can promote lung tissue repair in mice with severe influenza pneumonia. Singer discusses this breakthrough and how it could lead to an effective cellular therapy for patients with severe viral pneumonia and acute respiratory distress syndrome in the future. 

Alex spoke to Emily Amitin, Director of Development for American Lung Association in Metro NY & NJ, and Nicole Sturiano, Event Chair for American Lung Association on Long Island. They discuss their upcoming walk and how to get involved with the cause.

In this interview, Dr.SHIVA Ayyadurai, MIT PhD, Inventor of Email, Scientist, Engineer and Candidate for President, Talks about Bitter Melon on Lung Health: A Whole Systems Approach

 Today on Beating Cancer Daily, Saranne welcomes back Jacqui Bryan, a functional medicine expert, for an enlightening discussion on lung health and cancer survivorship. With humor and practical advice, they explore strategies to protect lung health, whether you are affected by lung cancer, Stage IV metastases, or simply wish to optimize respiratory wellness. Drawing from their combined 55 years of cancer survivorship, Saranne and Jacqui offer tips for improving air quality at home, nutrition plans, the impact of laughter, the role of physical activity, and how personalized self-care can empower anyone to breathe easier; physically and emotionally. Jacqui Bryan is a certified nutrition specialist, registered nurse, whole health educator, and certified health coach. Her expertise in functional medicine has helped countless clients create sustainable self-care plans during and after cancer treatment. Having contributed to over 100 previous episodes, Jacqui is recognized for her patient-centered approach, deep research skills, and commitment to making health education accessible and actionable. "Supporting our lungs isn't just about not smoking. It's about nutrition and lifestyle habits that we need to take into consideration when we're keeping this vital system healthy." ~Jacqui Bryan Today on Beating Cancer Daily:·     Why air quality (HEPA filters, houseplants, environmental mindfulness) is foundational to lung health, especially for those facing cancer or chronic lung issues·     The importance of understanding and managing symptoms such as persistent cough, chest tightness, or fatigue for early intervention·     Aerobic activity, breathing exercises, and even laughter are essential daily practices for maintaining and rehabilitating lung capacity·     Food-first approaches, prioritizing antioxidants, omega-3s, vitamins C and E, carotenoids, magnesium, and minimizing ultra-processed foods, reduce inflammation and aid lung function·     Hydration supports respiratory wellness, making removal of lung irritants easier·     Personalized nutrition and self-care are vital, from food journals to consulting healthcare providers for tailored lung-friendly diet and possible supplements·     Supplements like vitamin D, magnesium, omega-3s, NAC, and quercetin can support lung health but should be supervised by medical professionals, especially during cancer treatment·     Laughter has measurable benefits for lung health and emotional resilience, but as always, listen to your body and individualize your approach Guest Contact Information: Jacqui Bryan: JacquiBryan.com 2025 People's Choice Podcast Awards Finalist Ranked the Top 5 Best Cancer Podcasts by CancerCare News in 2024 & 2025, and #1 Rated Cancer Survivor Podcast by FeedSpot in 2024 Beating Cancer Daily is listened to in over 130 countries across 7 continents and features over 390 original daily episodes hosted by Stage IV survivor  Saranne Rothberg.   To learn more about Host Saranne Rothberg and The ComedyCures Foundation:https://www.comedycures.org/ To write to Saranne or a guest:https://www.comedycures.org/contact-8 To record a message to Saranne or a guest:https://www.speakpipe.com/BCD_Comments_Suggestions To sign up for the free Health Builder Series live on Zoom with Saranne and Jacqui, go to The ComedyCures Foundation's homepage:https://www.comedycures.org/ Please support the creation of more original episodes of Beating Cancer Daily and other free ComedyCures Foundation programs with a tax-deductible contribution:http://bit.ly/ComedyCuresDonate THANK YOU! Please tell a friend whom we may help, and please support us with a beautiful review. Have a blessed day! Saranne  

Autumn is the season of Metal in TCM, a time to let go, create clarity, and strengthen the Lung and Large Intestine. In this episode we explore its ties to dryness, grief, and boundaries, along with lifestyle and herbal approaches to support the season. You can read the full interview here: https://www.mayway.com/blogs/articles/fall-and-the-metal-element-season-of-refinement-and-releaseSee our Monthly Practitioner Discounts https://www.mayway.com/monthly-specialsSign up for the Mayway Newsletterhttps://www.mayway.com/newsletter-signupFollow ushttps://www.facebook.com/MaywayHerbs/https://www.instagram.com/maywayherbs/

Dr. David Goff leads a $2.1 billion cardiovascular research portfolio at the National Heart, Lung, and Blood Institute, driving breakthroughs in maternal health, precision medicine, and inclusive data science. His work has helped set the national research agenda while uplifting the culture of public service. As a 2025 Arthur S. Flemming Award recipient, Dr. Goff joins us to reflect on the science, the service, and what's next.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Your stress response doesn't just affect your mind...     It can directly impact your lungs as well.     Whether it's asthma, allergies, chronic congestion, or lingering post-viral symptoms, stress may be playing a bigger role than you think.     On today's show, I want to explore the HPA Lung Axis: the powerful connection between your brain, adrenals, and lungs, and how stress hormones like cortisol can trigger inflammation, weaken your immune system, and make it harder to fight off infections.     So join me on today's Cabral Concept 3534 as we break down how this brain-adrenal-lung connection works, why it keeps so many people stuck in cycles of inflammation, and what you can do to rebalance your body and breathe easier.     Enjoy the show!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3534 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral

A talk with John Shero - CEO of Visionary Wellness & Imaging about the importance of lung health and preventive body scans.See omnystudio.com/listener for privacy information.

17 Oct 2025 - Lung cancer trial builds momentum, breast cancer study begins

David Crosby has been through a lot. He has had a double lung and kidney transplant, fought skin cancer, and was placed in a coma from complications after getting Covid-19…And yet, a few days ago, David completed the Chicago Marathon!He joins Andrea to discuss this amazing feat…Image: Road Runners Club of America

Join us as we dive into the world of dairy consulting and the cutting-edge use of lung ultrasound in herd health management.

Where did you go Joe DiMaio? And Katt Stevens, whatever happened to him after he gave up secular music and started performing on BET ComicView? Peanut oil vapes come in handy when you need to ensure your child never develops a peanut allergy that excludes them from dinner at a Norwegian style household. Dog oil works on the same principle. Travis Kelce is going to be in the new Hennessy ad campaign dressed like Cole Campbell

Your stress response doesn't just affect your mind...     It can directly impact your lungs as well.     Whether it's asthma, allergies, chronic congestion, or lingering post-viral symptoms, stress may be playing a bigger role than you think.     On today's show, I want to explore the HPA Lung Axis: the powerful connection between your brain, adrenals, and lungs, and how stress hormones like cortisol can trigger inflammation, weaken your immune system, and make it harder to fight off infections.     So join me on today's Cabral Concept 3534 as we break down how this brain-adrenal-lung connection works, why it keeps so many people stuck in cycles of inflammation, and what you can do to rebalance your body and breathe easier.     Enjoy the show!   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3534 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Hughesy played Quick Draw in the studio and reminded us why he’s a legend… and a casualty. While chasing glory on the AFL Legends field, he copped a brutal hit that broke ribs and punctured a lung, but still kicked a goal from 25 metres out. The man’s competitive streak clearly doesn’t take a day off even recovering from major injuries, he was straight back to cheeky banter and hand-eye reflexes in the Quick Draw showdown.See omnystudio.com/listener for privacy information.

144: I'm coming to you from Ireland with a quick episode all about supporting your dog's lungs during seasonal changes. As we head into cooler weather, our pups are more prone to respiratory stress, coughing, and slower recovery from inflammation. I break down my Lung Tonic formula with reishi, black currant buds, calendula, and ginger, plus share why these herbs are so powerful for boosting immunity, reducing inflammation, and helping dogs breathe easier. Topics Discussed: → How can I support my dog's lungs naturally? → What herbs are best for canine respiratory health? → When should I worry about my dog's breathing rate? → Can dogs benefit from reishi and calendula? → What is the best lung tonic for dogs in fall and winter? Sponsored By: → Pug & Hound Apothecary Check Out Rita: → The Herbal Dog (Book) → Rita's Instagram → Facebook Group → My Courses → My Website and Store Produced By: Drake Peterson

RaeAnn Tucker from the Henry and Stark County Health Departments and First Choice Healthcare joined Wake Up Tri-Counties to talk about Mental Health Week, Lung Health Month, Insurance Navigators, Flu Shots, and COSSUP Services in Stark County. Mental Illness Awareness Week runs from October 5th to 11th, and local agencies are urging Tri-Counties residents to seek help when facing emotional or psychological challenges. First Choice Healthcare and the Henry and Stark County Health Departments are spotlighting community support as essential, noting that dedicated professionals offer a range of mental health services. Residents looking for assistance can reach out to their Kewanee office at 309-852-5272. In health news, a drive-thru adult flu shot clinic is scheduled for October 17th from 10 AM to 1 PM at 110 N. Burr Blvd., Kewanee, delivering vital protection this season.

Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Although precision medicine has improved outcomes for many patients, certain rare genetic mutations are still poorly understood, particularly in regions with limited access to genomic testing. Such mutations involve the HER2 gene, better known for its role in breast cancer but also implicated in a small subset of lung cancers. HER2 mutations are found in approximately 2–4% of non-small cell lung cancer (NSCLC) cases and create unique challenges. These tumors can vary significantly in how they appear under a microscope and in how they respond to treatment. Adding to the complexity, most diagnostic and treatment guidelines are based on research from high-income countries, which may not reflect the genetic diversity seen in other parts of the world. To help close this knowledge gap, researchers in Northeastern Brazil conducted one of the first detailed investigations into HER2-mutated NSCLC in Latin America. Their study, recently published in Volume 16 of Oncotarget, reveals a complex and often overlooked form of the disease, highlighting the need for broader access to targeted therapies in underserved populations. Full blog - https://www.oncotarget.org/2025/10/08/new-insights-into-her2-mutated-non-small-cell-lung-cancer-in-brazil/ Paper DOI - https://doi.org/10.18632/oncotarget.28737 Correspondence to - Fabio Tavora - stellacpak@outlook.com Abstract video - https://www.youtube.com/watch?v=hr5R9iDBFFI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28737 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, HER2 mutation, NSCLC, lung cancer, targeted therapy, genomic profiling To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Functional synapses between brain cells and cancer cells are key to the metastatic growth, according to new findings from two independent teams.

Get Your SUPER-SUPPLIMENTS HERE: https://vni.life/wam Use Code WAM15 & Save 15%! Life changing formulas you can't find anywhere else! DITCH YOUR DOCTOR! https://www.livelongerformula.com/wam Get a natural health practitioner and work with Christian Yordanov! Mention WAM and get a FREE masterclass! You will ALSO get a FREE metabolic function assessment! GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Use code JOSH to save money! GET YOUR WAV WATCH HERE: https://buy.wavwatch.com/WAM Use Code WAM to save $100 and purchase amazing healing frequency technology! Josh Sigurdson reports on a new study out of South Korea confirming that both the mRNA and non-mRNA "Covid" vaccines caused a massive heightened risk of 6 cancers after studying the vaccinated for 2 years. The study looks at 3 main groups. The unvaccinated, the vaccinated and the vaccinated and boosted. The results show the following: Overall cancer risk increased 27%. Breast cancer, 20%. Colorectal cancer, 28%. Gastric cancer, 34%. Lung cancer, 53%. Prostate cancer, 69%. Thyroid cancer, 35%. Now, this is one of many studies that have proven these injections cause cancer. In fact, many studies have far higher numbers. Moderna admitted in front of a House hearing that their mRNA vaccines caused cancer. Pfizer which just got $70 billion from President Trump knowingly hid evidence that their vaccines caused cancer in children which they attempted to cover-up before being uncovered in court. Croatian pathologist Ivana Pavic claims that 65% of cancer cases recieved one or more covid injections. This it a bio war crime. It's not just the vaccines! From cell towers to fluoride, from pesticides forming poison clouds over populations to stratospheric aerosol geoengineering. Let's not forget mRNA meat and Moderna's push to spray mRNA pesticides on our fruits and vegetables. We are all under attack. There are many natural treatments and preventatives like apricot seeds (laetrile) as well as CBD-A. The question is, will people take preventatives seriously or wait until they're sick which we hope doesn't happen to any of you. Stay tuned for more from WAM! HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-keep-wam-alive/# GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/ USE Code WAM to save 5% plus free shipping! BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson PURCHASE MERECHANDISE HERE: https://world-alternative-media.creator-spring.com/ PayPal: ancientwonderstelevision@gmail.com JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media For subscriber only content! Pledge here! Just a dollar a month can help us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2025

Người ta nghi ngờ liệu Úc có thể giải quyết được vấn đề nguồn cung nhà ở đáng kể trong vài năm tới hay không, và đặt ra câu hỏi về mục tiêu "tham vọng" năm 2029 của chính phủ. Vậy, chúng ta có thể làm gì?

Full article: Central Tumor Location in Resected Lung Adenocarcinoma: Association with Recurrence and Survival Outcomes What is the association of tumor location with lung cancer outcomes? Antonino Andrea Blandino, MD, discusses the article by Ahn et al. exploring prognostic implications of central location for resected lung adenocarcinoma. 

Ying Hui Low, MD, FASA, FASE; Mitchell Fuller, MD; William Lao, MD

10秒分清 “long” 与 “lung”！口语不再尴尬前几天又有一位小伙伴留言说，分不清“long”和“lung”,今天，卡卡老师就来帮大家清晰区分这两个单词的地道发音。long [lɒŋ]adj. 长的；长时间的；adv. 长时间地；n. 长时间；长距离发音需注意：英式发音：核心元音 [ɒ] 是短元音，嘴唇撅圆向中间聚拢，发音短促有力，尾音 [ŋ] 是后鼻音，舌根轻轻后抬贴住软腭，气流从鼻腔送出；美式发音：核心元音会比英式发音中的[ɒ]，下巴稍微下降；例句：This winter holiday will be very long.这个寒假会很长。lung [lʌŋ]（英式 / 美式）n. 肺（人体呼吸器官，常用复数形式 lungs）发音要点：核心元音 [ʌ] 是短元音，嘴巴自然张开，上下齿一根小拇指的宽度最为自然，发音短促不拖沓；例句：Regular exercise can help keep your lungs healthy.规律运动有助于保持肺部健康。原声听力：With his long stride, he often overtakes me.他步子大，所以经常走得比我快。These trees are the lungs of the earth.这些树木可谓为地球之肺。更多卡卡老师分享公众号：卡卡课堂 卡卡老师微信：kakayingyu001送你一份卡卡老师学习大礼包，帮助你在英文学习路上少走弯路

JCO PO authors Dr. Abhishek Tripathi and Dr. Salvador Jaime-Casas at City of Hope Comprehensive Cancer Center share insights into their article, “Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma.”  Host Dr. Rafeh Naqash and Drs. Tripathi and Jaime-Casas discuss a novel understanding of the genomic alterations underlying SCBC, revealing actionable mutations that could serve as potential targets for improved clinical outcomes. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, I am thrilled to be joined by Dr. Abhishek Tripathi, Associate Professor in the Department of Medical Oncology and Experimental Therapeutics Research at the City of Hope Comprehensive Cancer Center, as well as his mentee, Dr. Salvador Jaime-Casas, postdoctoral research fellow and first author of the JCO Precision Oncology article entitled "Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared with Urothelial Carcinoma and Small Cell Lung Carcinoma". At the time of this recording, our guest disclosures will be linked in the transcript. Abhishek and Salvador, welcome to our podcast and thank you for joining us today. This is a very interesting topic given that at least the landscape for neuroendocrine carcinomas, where small cell lung cancer is on one end of the spectrum, has been changing, at least on the lung cancer side, with recent approvals and some new ADCs. So, of course, understanding the genomic and transcriptomic similarities or differences between pulmonary small cell and extrapulmonary small cell is of huge interest. Could you tell us a little bit about small cell bladder cancer, current approaches to treatment of small cell bladder cancer, and then why you wanted to investigate that in this project as far as the genomic differences or similarities are concerned? Dr. Salvador Jaime-Casas: Well, first of all, thank you very much for having me. I am very excited to be here. And really what served as backbone for this research project was the notion that there is a currently evolving genomic landscape in the area of bladder cancer. We know this is a highly heterogeneous disease when it comes to molecular underpinnings and mutational profile. Specifically, we know that the most common histologic subtype is urothelial carcinoma. Small cell bladder cancer represents a histology that is found in less than 1% of all bladder cancer cases. However, it is one of the most aggressive histologies. It presents with a very poor prognosis to patients and very poor response to treatment, which is why we attempted to really elucidate what is the mutational profile behind this and provide a comparison contrast between small cell bladder cancer, small cell lung cancer, and conventional urothelial carcinoma. As your question mentioned, in terms of treatment, the conventional urothelial carcinoma and small cell bladder cancer are two distinct pathways when it comes to treatment algorithms. We know that in the current era there are newer and newer drugs being developed for conventional urothelial carcinoma. We have perioperative immunotherapy in the context of metastatic disease. We have antibody-drug conjugates such as enfortumab vedotin. But really, this amazing track record of drug development hasn't been mirrored in small cell bladder cancer. And here most of the therapy is usually extrapolated from studies from other small cell histologies like you mentioned earlier, small cell lung cancer has given some form of background in terms of what therapies are used here. Cytotoxic chemotherapy, for some patients with localized disease and small cell bladder cancer, concurrent chemotherapy and radiotherapy or perioperative cytotoxic chemotherapy have been the cornerstone of treatment for many years now. However, like I mentioned, the oncologic outcomes are very suboptimal when it comes to comparing it with other disease histologies, which is why we really wanted to describe the landscape here and provide this comparison across three different groups. For this particular study, we leveraged the Tempus dataset. So, include patients with urothelial carcinoma with small cell bladder cancer and small cell lung cancer. We included their demographic information, as well as the frequency of most common genomic alterations identified. And really, it was a very comparable Table 1. We see the demographic data across the three groups was very similar. One key thing that we identified was the female prevalence was a little bit lower in patients with small cell bladder cancer when compared to small cell lung cancer. But other than that, the age, race, ethnicity, was comparable across groups, and even the smoking history. Most of the patients in this cohort were former smokers, which we believe comes to explain that regardless of any mutational profile that we talked about in a few minutes, there are shared commonalities between these histologies and shared environmental exposures and risk factors that are going to be implicated in the disease biology for these three histologies. Dr. Rafeh Naqash: Thank you so much, Salvador, for that useful background. I would like to shift to Abhishek real quick. Abhishek, you are a practicing clinician, you have led several studies in the GU space, especially bladder. Based on what you see in the small cell lung cancer space, how drug development is shaping up, which aligns with what you are trying to evaluate in this paper as targets, how do you see some of that being implemented for small cell bladder cancer in the current era and age? Abhishek Tripathi: Thanks so much for the excellent question, Rafeh. As a GU investigator, small cell bladder cancer has always lagged behind in some regards regarding enrollment abilities for the novel clinical trials. And small cell lung cancer has paved the way and led the development of a lot of these drugs across the board. With the most recent sort of drugs targeting DLL3 already approved and several antibody-drug conjugates currently in development. That actually translates really well to how we should approach drug development in bladder cancer. What we saw in the study is that although there are overlaps and similarities between small cell lung cancer and small cell bladder cancer, there are also certain differences. So the long-term assumption that all therapies for small cell bladder cancer can be extrapolated to small cell bladder], may or may not be true, and I think it is high time that we specifically investigate these novel agents in tissue-specific small cell carcinomas. To that effect, we are excited to be participating in trials that are looking at some of the novel DLL3 targeted agents, specifically bispecific antibodies and T cell engagers so to speak, and antibody-drug conjugates that are now starting to open enrollment specifically in non-lung cancer cohorts to evaluate its efficacy. So overall, I think studies like this have the opportunity to identify more putative targets for organ-specific development of these novel agents. Dr. Rafeh Naqash: Absolutely, I could not agree more. I think tumor-agnostic therapies definitely have a place, but not all therapies work the same in different tumors with a similar histological or genomic background because there are definitely differences. So now going to the comparison that Salvador, you guys did in this project, could you help us understand what are some of the things you looked at, what were some of the commonalities and the differences, and what were some of the conceptual thoughts that come out from those results? Dr. Salvador Jaime-Casas: Of course. So, the first thing that we identified was which were the most frequent molecular alterations across these histologies. We actually provided a table showcasing how the most common mutations that we identified were TP53, TERT, RB1. However, like Dr. Tripathi mentioned, the distinction between these histologies is notable in the sense that some are more predominant in small cell-pertaining cancers such as bladder cancer and lung cancer. While some others are more common in bladder-pertaining malignancies like urothelial carcinoma and small cell bladder cancer. For instance, we saw that TP53 and RB1 were significantly more evident in small cell histologies, both small cell bladder cancer and small cell lung cancer, as opposed to conventional urothelial carcinoma, which really this mirrors what is known about these mutations and what has been published. These are markers associated with more aggressive disease with a worse prognosis and even to resistance to treatment. We also identified how TERT mutations were characteristically more prevalent in small cell bladder cancer as opposed to small cell lung cancer, as well as in urothelial carcinoma. TERT mutations were more commonly identified than in small cell lung cancer. And we give a long list of these mutations that we identified, but really what we wanted to underscore here was, A, the most common mutations across histologies; B, the most common co-occurring mutations where we saw that these are not mutually exclusive. A lot of patients had co-occurring TP53 and RB1 or RB1 and TERT or RB1 and ARID1A, really elucidating how heterogeneous this molecular landscape is across histologies. And the third one that we believe really brings down the clinical impact of this research was evidencing the idea of clinically actionable mutations. We also provided a table here showcasing how mutations like FGFR, DLL notch pathway, HER2, were evident in these histologies, and what is the current status of some clinical trials evaluating different drug designs for these mutations. Like Dr. Tripathi mentioned in the context of FGFR, approximately 6% of our cohort with small cell bladder cancer showcased mutations in FGFR3. However, up to 14% of them had mutations in any FGFR gene, which really underscores the notion that drugs like erdafitinib, which have been introduced in the market in recent years, could potentially showcase some response in the space of small cell bladder cancer. We actually provide the description of two trials, phase two, phase three trials, that are evaluating erdafitinib in the context of high-risk non-muscle invasive bladder cancer and even metastatic urothelial carcinoma. Like Dr. Tripathi mentioned as well, antibody-drug conjugates, another very interesting area of drug development targeting HER2, we included evidence on how disitamab vedotin and trastuzumab deruxtecan are currently being explored across different phase two and phase three clinical trials, both as part of basket trial designs for solid malignancies expressing HER2, but also for patients with urothelial carcinoma where there is evidence of HER2 expression. So, we believe that the landscape is shifting in the right direction in the sense that therapies are becoming much more personalized and targeted against these known molecular profiles. Dr. Rafeh Naqash: Thank you, Salvador, for summarizing some of those very interesting results and providing a very unique conceptual context to that. I would like to go to Abhishek this last portion. Of course, I am sure you guys will expand on this work and there are a lot of other interesting things that will likely come out from this work and hopefully you will publish that in JCO PO. But one of the very important things that I wanted to highlight from this podcast specifically was the science is obviously very interesting, but I feel the more important interesting aspect is giving trainees and fellows, residents, mentorship opportunities, mentoring them and giving them lead roles in projects like this, which is what Dr. Tripathi has successfully done for you in this project, Salvador. So, Abhishek, as somebody I have known for a couple of years now, more than a couple of years, as a very successful clinical translational investigator in the GU space in the early phase setting, Abhishek, really briefly, within a minute, could you tell us about your journey and what are some of the things that have worked for you as an early career investigator that you have learned from, and then your journey of mentorship, how has that been for you and what are some of the things that you take home from your mentorship role? Abhishek Tripathi: Absolutely. And as you mentioned, mentorship has been pivotal for all early career investigators for them to really succeed. So, my journey, as you know, I started off as an early career investigator at another institution, and I think I owe it to my mentors even at that time and even now who are helping me develop some of these newer translational and clinical trial ideas, creating opportunities where we could really showcase some of the interesting work that we are doing. That actually goes a long way in terms of creating independence as an established investigator. And I think the sooner we start off with mentorship prospects, I think the better it is. And paying it forward, I think I have been lucky to have mentees like Salvador who are just extremely talented, really committed, and goal-oriented. He really led the project right from the beginning in terms of initial analyses and looking up all the sort of correlative studies that we could do and the contextual data between small cell lung cancer and bladder cancer that we have delved into for the past several years. And it really showcases the ability of young mentees like Salvador to really excel given the right guidance and the support. As a mentor, it has been a really rewarding experience. It is really helpful to actually learn from some of these mentees as well as to approach the same problem from a different angle and different thought process and guide them through the study. So, it has been incredibly helpful and rewarding both being a mentee and a mentor over the past several years as I have transitioned. Dr. Rafeh Naqash: Thank you, Abhishek, for those very insightful comments on how both being a mentee and being a mentor helps shape you as an individual as well. And then you take a lot of pride in the success of your mentees. Now real quick, Salvador, could you tell us a little bit about yourself, you know, how you ended up at City of Hope under Dr. Tripathi's mentorship and what are some of the next important things that you are looking forward to doing? Dr. Salvador Jaime-Casas: So, a little bit about who I am. I did medical school in Mexico City. I was born and raised there, and towards the end of my medical training, I started to be engaged in research projects. And through one of my mentors in Mexico, I was actually introduced to the team here at City of Hope, including Dr. Tripathi. And through this, we got the opportunity to have some conversations about what I wanted to do, become a physician-researcher in the area of genitourinary oncology and hopefully my transition to residency in a few years. And that is how I came to be his mentee here at City of Hope. I think it has been a very rewarding experience, like Dr. Tripathi said, having such an incredible mentor and really being with him both in the academic setting and in the clinical setting, in patients with clinic, seeing this curiosity and all these clinical trials, all of this evidence that we have coming together to generate this insight. Dr. Rafeh Naqash: Thank you so much for both the scientific insights, as well as the journey of being a mentee for you, Salvador, and as a mentor for you, Abhishek. I really enjoyed talking to you guys about both aspects here today and hopefully we will see more of your work, Abhishek and Salvador, as far as understanding the transcriptomic heterogeneity in neuroendocrine tumors or neuroendocrine cancers of the bladder. Dr. Salvador Jaime-Casas: Thank you very much. Thank you for having us. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Do not forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at ASCO.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.   Dr. Abhishek Tripathi Disclosures Consulting or Advisory Role:  Company: Aadi biosciences, Seattle Genetics/Astellas, Exelixis, Bayer, Gilead Sciences, Pfizer, Deka biosciences Speakers' Bureau: Company: Sanofi

Lung cancer is one of the world's biggest killers. Today, we explore why, and how medical research into this disease is seeing the development of better diagnostic tools, cancer treatments and even a vaccine to prevent tumours from taking hold in the first place... Like this podcast? Please help us by supporting the Naked Scientists

RaeAnn Tucker joined Wake Up Tri-Counties to discuss National Lung Day, the Drive-Thru Flu Shot Clinic, World Contraception Day, Suicide Awareness and Prevention Month, and Insurance Navigators. The Henry and Stark County Health Departments are encouraging community participation in several vital health initiatives. On October 17th, adults can receive the seasonal trivalent flu vaccine through a drive-thru clinic at 110 N. Burr Blvd in Kewanee, from 10 AM to 1 PM. Attendees should bring their Medicare or insurance card, or $60 in cash or check. Meanwhile, World Contraception Day, observed on September 26th, highlights the availability of accessible, confidential reproductive health services at First Choice Healthcare locations. September also marks Suicide Prevention Month, with local providers promoting the 988 Suicide & Crisis Lifeline and offering mental health support for all residents. Call 309-852-5272 for more information.

In this episode of the Smarter Not Harder Podcast, Dr. Vivek Lal joins Dr. Scott Sherr for a groundbreaking and eye-opening conversation about the gut-lung axis — the overlooked connection between your microbiome and your ability to breathe, perform, and recover. From inhaled probiotics to AI‑driven lung therapy, this episode bridges clinical science and next‑gen wellness in a way you've never heard before. Join us as we delve into: How gut bacteria directly influence lung inflammation, asthma, and COPD Why your lungs aren't sterile — and what lives in them might save your life The rise of inhaled postbiotics and what “air as medicine” really means Cutting-edge lung science: AI, organoids, omics, and future therapies This episode is for you if: You've never heard of the gut-lung axis but want to breathe, sleep, and recover better You or someone you love has asthma, COPD, or unexplained breathing issues You're fascinated by how microbiomes affect health far beyond the gut You want smarter, not harder, ways to optimize lung health and longevity You can also find this episode on…  YouTube: https://youtu.be/PZZw8ulAHiM  Find more from Dr. C. Vivek Lal, MD, FAAP: Resbiotic Nutrition: https://resbiotic.com/ LinkedIn: https://linkedin.com/in/c-vivek-lal-md-faap-20183913 Instagram: https://instagram.com/dr.viveklal/ Find more from Smarter Not Harder: Website: https://troscriptions.com/pages/podcast Instagram: https://instagram.com/troscriptions/ HOMeHOPe Symposium: https://homehope.org/homehope-symposium Get 10% Off your purchase of the Gut Lung Axis Module by using PODCAST10 at https://www.homehope.org Get 10% Off your Troscriptions order with code POD10 at https://www.troscriptions.com

 PodCast ChannelsVô Vi Podcast - Vấn Đạo  Vô Vi Podcast - Băn GiảngVô Vi Podcast - Nhạc Thiền

Study Discovers Increased Cancers After MRNA Vaccines, Bret Weinstein- Covid & mRNA: Harms and Damages Exposed Bret Weinstein- Covid & mRNA: Harms and Damages Exposed (NEW!) REMINDER: CDC Didn't Track VAERS Safety Signals John Campbell- Increased cancers after mRNA vaccines   Study- Covid & mRNA: Harms and Damages Exposed (NEW!) | DarkHorse https://youtu.be/zkrbZmYuRoY?si=_0yO0y5ftLacoVJ1 Bret Weinstein 512K subscribers 25,699 views Sep 5, 2025 A new article on the harms and hazards of both SARS-CoV2 and the mRNA biologics said to counter the virus. Full Episode: https://youtube.com/live/wQWkKrM3Dt8 Mentioned in this segment: Zywiec et al 2025. COVID-19 Injections: Harms and Damages, a Non-Exhaustive Conclusion. Journal of American Physicians and Surgeons, 30(3): https://jpands.org/vol30no3/zywiec.pdf ***** Join us on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.com Heather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.com Our book, A Hunter-Gatherer's Guide to the 21st Century, is available everywhere books are sold, including from Amazon: https://amzn.to/3AGANGg (commission earned) Check out our store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://darkhorsestore.org   REMINDER: CDC Didn't Track VAERS Safety Signals | DarkHorse https://youtu.be/u3UAyr6s7xc?si=VUoenskCyMdViArS Bret Weinstein 512K subscribers 16,906 views Sep 5, 2025 RFK Jr. fires the new director, after which other CDC officials resign, and eight former directors of the CDC pen a letter to the New York Times arguing that Kennedy is a hazard to our health. Bret Weinstein and Heather Heying discuss "The Plot Against Kennedy" in Episode 292 of The Evolutionary Lens. Full Episode: https://youtube.com/live/wQWkKrM3Dt8 Mentioned in this segment: NYT op-ed #2 from former CDC directors: We Ran the C.D.C.: Kennedy Is Endangering Every American's Health: https://www.nytimes.com/2025/09/01/op... Bret and Heather 132nd DarkHorse Podcast Livestream: 50 States not in a Roe https://youtube.com/live/usP2D_qGUZs CDC didn't monitor VAERS for COVID safety signals (June 2022): https://childrenshealthdefense.org/de...   Increased cancers after mRNA vaccines Watch this video at- https://youtu.be/3dnIGqUlluc?si=sDbAdXTgOsCiCLev Dr. John Campbell 3.25M subscribers 143,152 views Sep 5, 2025 COVID-19 vaccination, all-cause mortality, and hospitalization for cancer: 30-month cohort study in an Italian province https://pubmed.ncbi.nlm.nih.gov/40881... https://pmc.ncbi.nlm.nih.gov/articles... https://www.thefocalpoints.com/p/brea... The rate of first hospitalization for cancer of any site Unvaccinated group: 0.85% Vaccinated group (one or more doses): 1.15% N = 296,015 population Hospital admission with a cancer diagnosis, 3,124 (p less than 0.001). Vaccination with at least one dose Colon-rectal cancer HR: 1.34 Breast cancer HR: 1.54 Bladder cancer HR: 1.62 After three or more vaccine doses Breast cancer HR: 1.36 Bladder cancer HR: 1.43 All significant After one dose (180 days after) Rate of first hospital admissions for cancers All cancers: up 23% significant Colorectal: up 34% significant Lung: down = 10% Breast: up 54% significant Uterine: up = 75% Ovarian: up = 65% Prostate: up = 1% Bladder: up 62% significant Thyroid: up =58% Haematological: up = 33% After three dose (180 days after administration of third dose) All cancers: up = 9% Colorectal: up = 14% Lung: down = 5% Breast: up=36% significant Uterine: up = 20% Ovarian: up = 86% Prostate: down = 3% Bladder: up=43% significant Thyroid: down = 3% Haematological: up = 5% More about the study Population-wide cohort analysis Evaluating the risk of all-cause death and cancer hospitalization by SARS-CoV-2 immunization status. National Health System official data, entire population, Pescara province, Italy Followed from June 2021 (six months after the first vaccination) to December 2023. 296,015 residents aged ≥11 years Hospital admission with a cancer diagnosis, 3,124 16.6% were unvaccinated 83.3% received ≥1 dose 62.2% ≥3 doses. Compared with the unvaccinated, those receiving ≥1 dose showed a significantly lower likelihood of all-cause death Cancer hospitalization was significant only among the subjects with no previous SARS-CoV-2 infection Some cancer risks went down after 1 year (relative to 180 days) (But breast, ovarian and bladder went up at one year relative to 180 days after 1 vaccine dose) Given that it was not possible to quantify the potential impact of the healthy vaccinee bias and unmeasured confounders, these findings are inevitably preliminary.  

Join us for an in-depth conversation with Dr. Aahd Kubbara, a practicing pulmonologist, intensivist, and Assistant Professor of Medicine at the University of Minnesota Medical Center. Dr. Kubbara specializes in pulmonary, allergy, critical care, and sleep medicine, with advanced expertise in interstitial lung disease, asthma, and targeted biological therapies. In this episode, we explore the complexities of lung health and the latest strategies for preventing and managing chronic respiratory conditions: ·       How inflammatory lung diseases can cause long-term scarring. ·       The consequences of untreated or poorly managed asthma over time. ·       What pulmonary fibrosis is and the most effective approaches to treatment. ·       The risks of normalizing chronic respiratory symptoms. ·       Seasonal asthma triggers and how to reduce their impact. With years of experience at the Mayo Clinic and University of Nevada, as well as community pulmonary care practice, Dr. Kubbara offers insights into cutting-edge therapies, personalized medicine, and preventive strategies to maintain lung health. Learn more about Dr. Kubbara and his work in pulmonary medicine here! Episode also available on Apple Podcasts: https://apple.co/38oMlMr  Keep up with Dr. Aahd Kubbara socials here: Instagram: https://www.instagram.com/aahd_kubbara/?hl=en  X : https://x.com/aahdkubbara 

Microplastics were found to trigger cancer-like changes in healthy lung cells, including increased mobility, DNA damage, and activated survival pathways Inhaled particles bypass your body's defenses and embed deep in your lungs, where they silently disrupt cellular function without causing obvious inflammation A review of 31 studies confirmed that microplastics harm your lungs, gut, and reproductive organs even at exposure levels that mimic everyday life Smaller nanoplastics are especially dangerous because they cross into your bloodstream, reaching your liver, brain, and other organs where they cause long-term damage Natural strategies like psyllium, chitosan, probiotics, and autophagy-enhancing nutrients help trap and remove plastic particles before they're absorbed

Thoracic radiologists Jeffrey Kanne, Miranda Siemienowicz and Jonathan Chung discuss the current global status of lung cancer screening, offering tips and tricks for reading these studies. Meanwhile, Andrew and Frank talk about everything BUT pulmonary nodules: another shameful journal travesty, TB sniffer rats and ketamine epiphanies.   Lung cancer screening article ► https://radiopaedia.org/articles/lung-cancer-screening Retraction Watch - Tin Man Syndrome ► https://retractionwatch.com/2025/08/15/tin-man-syndrome-case-plagiarized-from-hoax-sleuths-say/ Those TB detecting rats ► https://apopo.org/what-we-do/detecting-tuberculosis Become a supporter ► https://radiopaedia.org/supporters Get an All-Access Pass ► https://radiopaedia.org/courses/all-access-course-pass Radiopaedia Community chat ► http://radiopaedia.org/chat Ideas and Feedback ► podcast@radiopaedia.org   The Reading Room is a radiology podcast intended primarily for radiologists, radiology registrars and residents. 

This week, Johnny returned from a bad hotel, told us about the landlord at Gatwick, and quizzed Harry on his apple crumble and his nan-in-law. Hear Johnny on Radio X every weekday at 4pm across the UK on digital radio, 104.9 FM in London, 97.7 FM in Manchester, on Global Player or via www.radiox.co.uk

Good Morning,Nan tho tha hna maw? Tuzing zong morning devotion i hrawm ti dingin kan in sawm hna. A kan hruaitu: Rev. Ram MaungTitle: Na Lung Dong HlahLunglawmhnak ngan pi he,CAPT: CEBC Arts Production Team--Music By Peder B. Helland